ABEO.US Abeona Therapeutics Inc

Healthcare Biotechnology USA Stocks
2.15 USD
Close of Nov 13, 2026
2.22 7.65
Market cap
USD 133M
P/E
-
P/B
1.12x
ROE
-44.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ABEO.US undervalued?

Graham number

The Graham number of Abeona Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Abeona Therapeutics Inc fundamental analysis

No fundamental analysis for Abeona Therapeutics Inc yet.

Abeona Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Abeona Therapeutics Inc

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition,…

Full company profile